Compare Crispr Therapeutics AG (CRSP) vs Deere & Company (DE) Price & Performance

CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.

The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.

Deere & Company (DE) trades at $656.87, down 3.8% on the day, showing near-term weakness despite strong earnings beats in recent quarters. The stock maintains a bullish analyst consensus with a $731.20 price target, representing 11% upside potential. Recent financial performance shows declining revenue from $60.2B in 2023 to $44.7B in 2025, though the company continues generating robust operating cash flow exceeding $7B annually. Technical indicators suggest bearish momentum with the stock trading below key resistance levels.

Deere presents a mixed investment case with attractive valuation upside but faces cyclical headwinds in agricultural equipment demand. The company's AI initiatives and dividend payments provide stability, while declining profit margins and elevated debt levels warrant caution. Wall Street remains optimistic with 43% buy ratings, though technical weakness suggests potential near-term pressure before fundamental strength prevails.